To meet market demand for highly effective, low-toxic anti-tumor drugs, the company invested in R&D to upgrade the technology of a specific anti-tumor pharmaceutical intermediate. By optimizing the reaction route and improving the production process, the company not only reduced production costs by 30% but also controlled the product impurity content to below 0.1%. The technological upgrade enabled large-scale mass production, supplying 20 tons of high-quality anti-tumor pharmaceutical intermediates to downstream pharmaceutical companies monthly, helping to increase the production capacity of multiple anti-tumor drugs.